Lung Center, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
PLoS One. 2022 Jul 21;17(7):e0271004. doi: 10.1371/journal.pone.0271004. eCollection 2022.
Sleep apnea (SA) is a prevalent disorder characterized by recurrent events of nocturnal apnea originating from obstructive and/or central mechanisms. SA disrupts normal sleep and can lead to a series of complications when left untreated. SA results in intermittent hypoxia which has an impact on the cardio- and cerebrovascular system. Hospitalized patients with SA typically have a greater burden of comorbidity, a longer length of hospital stay, but may show an improvement of in-hospital mortality compared to patients without diagnosed SA. The reason for this survival benefit is controversial and we aimed to clarify this protective effect in the light of predictive factors including SA-associated comorbidities using a nation-wide hospitalization database.
Data were extracted from a nation-wide hospitalization database provided by the Swiss Federal Office for Statistics. Hospitalized patients with a SA co-diagnosis were extracted from the database together with a 1:1-matched control population without SA. Overall, 212'581 patients with SA were hospitalized in Switzerland between 2002 and 2018. Compared to the controls, SA cases had a longer median length of hospital stay (7 days; 95% CI: 3 to 15 vs. 4 days; 95% CI: 2 to 10) (p < 0.001) and a higher median number of comorbidities (8 comorbidities; IQR: 5 to 11 vs. 3 comorbidities; IQR: 1 to 6) (p < 0.001). The risk of in-hospital mortality was lower in the SA cases compared to the controls (OR: 0.73; 95% CI: 0.7 to 0.76; p < 0.001). SA was associated with a survival benefit in hospitalizations related to 28 of 47 conditions with the highest rate of in-hospital death. Sixty-three comorbidities were significantly over-represented in SA cases among which obesity, hypertension and anatomic nasal deviations were associated with a significant decrease of in-hospital mortality.
Compared to matched controls, SA was associated with significant and relevant inpatient survival benefit in a number of most deadly conditions. Within SA-patients, associated comorbidities mostly correlated with a poorer prognosis, whereas obesity and hypertension were associated with an improved in-hospital mortality.
睡眠呼吸暂停(SA)是一种普遍存在的疾病,其特征是夜间反复发作的呼吸暂停,源于阻塞性和/或中枢机制。SA 会扰乱正常睡眠,并在未经治疗的情况下导致一系列并发症。SA 导致间歇性缺氧,对心血管和脑血管系统有影响。患有 SA 的住院患者通常合并症负担更大,住院时间更长,但与未确诊的 SA 患者相比,住院死亡率可能有所改善。这种生存获益的原因存在争议,我们旨在根据包括与 SA 相关的合并症在内的预测因素,利用全国住院数据库来阐明这种保护作用。
数据来自瑞士联邦统计局提供的全国住院数据库。从数据库中提取出 SA 合并诊断的住院患者,并与没有 SA 的 1:1 匹配对照人群进行比较。总体而言,2002 年至 2018 年期间,瑞士共有 212581 例 SA 患者住院。与对照组相比,SA 病例的中位住院时间更长(7 天;95%CI:3 至 15 比 4 天;95%CI:2 至 10)(p<0.001),合并症中位数更多(8 种合并症;IQR:5 至 11 比 3 种合并症;IQR:1 至 6)(p<0.001)。与对照组相比,SA 病例的院内死亡率较低(OR:0.73;95%CI:0.7 至 0.76;p<0.001)。SA 与 47 种与院内死亡率最高相关的疾病中的 28 种相关的住院治疗有显著的生存获益。在 SA 病例中,63 种合并症明显更为常见,其中肥胖症、高血压和解剖性鼻偏曲与院内死亡率显著降低相关。
与匹配的对照组相比,SA 与一些最致命疾病的显著和相关的住院生存获益相关。在 SA 患者中,相关合并症大多与预后较差相关,而肥胖症和高血压与改善院内死亡率相关。